Reoto Takei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Reoto Takei has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Yasuhiro Kondoh
Department of Respiratory Medicine and Allergology, Aichi Medical University, 1-1 Yazako Karimata, Nagakute, Aichi, 480-1195, Japan; Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160, Nishi-oiwake-cho, Seto, Aichi, 489-8642, Japan
7 shared publications - Yasuhiko Yamano
Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan
6 shared publications - Tomoki Kimura
Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan
5 shared publications Toshiki Yokoyama
Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan; Department of Emergency and Intensive Care Medicine, Intensive Care Unit, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan
5 shared publications- Toshiaki Matsuda
Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan
4 shared publications Fumiaki Tokioka
Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan
3 shared publications
Latest Publications
- 20 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 662-670
Impact of Pulmonary Artery Pressure on the Response to Oxygen Administration for Exertional Desaturation in Interstitial Lung Disease
Background and Objective: Patients with interstitial lung disease (ILD) often experience exertional desaturation even without resting hypoxemia, resulting in limited exercise capacity. While oxygen administration can extend exercise time in a majority of patients with ILD, the factors determining the oxygen effects are unclear. We aimed to investigate the clinical significance of respiratory and pulmonary haemodynamic parameters for the oxygen effects on exercise time in patients with ILD.Methods: We retrospectively analysed patients with ILD who underwent comprehensive evaluation including right heart catheterisation from 2017 to 2021. Patients were divided into oxygen responders, defined as an improvement of at least 100 s or 33% in exercise time with oxygen supplementation compared with medical air inhalation, and non‐responders. Univariate and multivariate logistic regression analyses were conducted to evaluate significant factors for oxygen responders.Results: Among 86 patients, 50 (58.1%) were oxygen responders. Pulmonary functional tests and ventilation parameters at cardiopulmonary exercise testing were similar between the groups. Mean pulmonary arterial pressure (mPAP) (21 mmHg vs. 19 mmHg, p = 0.049) was higher in oxygen responders. Univariate logistic analysis demonstrated that the ILD‐Gender‐Age‐Physiology index, mPAP, 6‐min walking distance, peak work rate, and lowest ventilatory equivalent for carbon dioxide were significant variables for oxygen effects on exercise time. Multivariate analysis demonstrated that elevated mPAP was independently associated with the oxygen effects on exercise time.Conclusion: Approximately 60% of the patients with ILD who experienced exertional desaturation without resting hypoxemia were oxygen responders. mPAP was associated with the oxygen effects on exercise time. image
- 20 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 662-670
Impact of Pulmonary Artery Pressure on the Response to Oxygen Administration for Exertional Desaturation in Interstitial Lung Disease
Background and Objective: Patients with interstitial lung disease (ILD) often experience exertional desaturation even without resting hypoxemia, resulting in limited exercise capacity. While oxygen administration can extend exercise time in a majority of patients with ILD, the factors determining the oxygen effects are unclear. We aimed to investigate the clinical significance of respiratory and pulmonary haemodynamic parameters for the oxygen effects on exercise time in patients with ILD.Methods: We retrospectively analysed patients with ILD who underwent comprehensive evaluation including right heart catheterisation from 2017 to 2021. Patients were divided into oxygen responders, defined as an improvement of at least 100 s or 33% in exercise time with oxygen supplementation compared with medical air inhalation, and non‐responders. Univariate and multivariate logistic regression analyses were conducted to evaluate significant factors for oxygen responders.Results: Among 86 patients, 50 (58.1%) were oxygen responders. Pulmonary functional tests and ventilation parameters at cardiopulmonary exercise testing were similar between the groups. Mean pulmonary arterial pressure (mPAP) (21 mmHg vs. 19 mmHg, p = 0.049) was higher in oxygen responders. Univariate logistic analysis demonstrated that the ILD‐Gender‐Age‐Physiology index, mPAP, 6‐min walking distance, peak work rate, and lowest ventilatory equivalent for carbon dioxide were significant variables for oxygen effects on exercise time. Multivariate analysis demonstrated that elevated mPAP was independently associated with the oxygen effects on exercise time.Conclusion: Approximately 60% of the patients with ILD who experienced exertional desaturation without resting hypoxemia were oxygen responders. mPAP was associated with the oxygen effects on exercise time. image
- 17 April 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (4) , 481-487
Characteristics, clinical findings, and treatment of idiopathic pulmonary fibrosis in Japanese patients registered with a medical subsidy system for intractable diseases
- 17 April 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (4) , 481-487
Characteristics, clinical findings, and treatment of idiopathic pulmonary fibrosis in Japanese patients registered with a medical subsidy system for intractable diseases
- Open Access
Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.
Open AccessReal-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.
- 15 March 2022
- Published by Wiley in Respirology
- Vol. 27 (5) , 333-340
Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype
Background and objective: The development of clinically progressive fibrosis complicates a wide array of interstitial lung diseases (ILDs). However, there are limited data regarding its prevalence and prognosis.Methods: We analysed consecutive patients seen for initial evaluation of a fibrosing form of ILD (FILD). Patients were evaluated for evidence of progressive fibrosis over the first 24 months of follow‐up. We defined a progressive phenotype as the presence of at least one of the following: a relative decline in forced vital capacity (FVC) of ≥10%; a relative decline in FVC of ≥5%–p p p p = 0.42).Conclusion: Over one‐fourth of non‐IPF FILD patients develop a progressive phenotype compared to approximately 60% of IPF patients. The survival of non‐IPF FILD patients with a progressive phenotype is similar to IPF.
- 15 March 2022
- Published by Wiley in Respirology
- Vol. 27 (5) , 333-340
Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype
Background and objective: The development of clinically progressive fibrosis complicates a wide array of interstitial lung diseases (ILDs). However, there are limited data regarding its prevalence and prognosis.Methods: We analysed consecutive patients seen for initial evaluation of a fibrosing form of ILD (FILD). Patients were evaluated for evidence of progressive fibrosis over the first 24 months of follow‐up. We defined a progressive phenotype as the presence of at least one of the following: a relative decline in forced vital capacity (FVC) of ≥10%; a relative decline in FVC of ≥5%–p p p p = 0.42).Conclusion: Over one‐fourth of non‐IPF FILD patients develop a progressive phenotype compared to approximately 60% of IPF patients. The survival of non‐IPF FILD patients with a progressive phenotype is similar to IPF.
- 1 January 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (1) , 99-107
The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease
- 1 January 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (1) , 99-107
The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease
- Open Access
- 19 October 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (11) , e0865
Anti‐MDA5 antibody‐positive clinically amyopathic dermatomyositis with diffuse alveolar damage diagnosed by transbronchial lung cryobiopsy: A case report
Diffuse alveolar damage (DAD) is known to be a pathological hallmark of acute respiratory distress syndrome or acute interstitial pneumonia, and to have a poor prognosis. We report a case of anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody‐positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP‐ILD), in which DAD was confirmed by transbronchial lung cryobiopsy at an early stage without respiratory failure. Although this patient initially did not show respiratory failure, his respiratory condition gradually worsened despite intensive immunosuppression therapy and he died 3 months later. Therefore, the early pathological findings of DAD did not match the clinical picture, which showed no respiratory failure. However, these findings were consistent with the subsequent course and poor outcome. Histological DAD, even in the absence of respiratory failure, may indicate a subsequent poor prognosis and explain the refractory course of RP‐ILD with anti‐MDA5 antibody‐positive CADM.
- 19 October 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (11) , e0865
Open AccessAnti‐MDA5 antibody‐positive clinically amyopathic dermatomyositis with diffuse alveolar damage diagnosed by transbronchial lung cryobiopsy: A case report
Diffuse alveolar damage (DAD) is known to be a pathological hallmark of acute respiratory distress syndrome or acute interstitial pneumonia, and to have a poor prognosis. We report a case of anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody‐positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP‐ILD), in which DAD was confirmed by transbronchial lung cryobiopsy at an early stage without respiratory failure. Although this patient initially did not show respiratory failure, his respiratory condition gradually worsened despite intensive immunosuppression therapy and he died 3 months later. Therefore, the early pathological findings of DAD did not match the clinical picture, which showed no respiratory failure. However, these findings were consistent with the subsequent course and poor outcome. Histological DAD, even in the absence of respiratory failure, may indicate a subsequent poor prognosis and explain the refractory course of RP‐ILD with anti‐MDA5 antibody‐positive CADM.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3276
Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis
Background: Attention has been focused on identifying cases with a progressive phenotype in interstitial lung abnormalities (ILA). Some ILA cases may be followed up as they are, some may be diagnosed with interstitial lung disease (ILD) as a result of work-up, including a surgical lung biopsy. Aims: To evaluate if the cases of idiopathic pulmonary fibrosis (IPF) with definition of ILA (ILA-IPF) differed from those of IPF without ILA (non-ILA-IPF). Methods: Of the patients diagnosed with IPF from January 2008 to July 2015, 149 ILA-IPF cases and 120 non-ILA-IPF cases were examined for various variables including disease progression and prognosis. ILA is defined based on the incidental identification of CT abnormality that are potentially compatible with ILD without previous clinical suspicion of ILD (Lancet Respir Med 2020; 8: 726–37). Results: In patients’ background at diagnosis of the two groups, significant differences were observed in age, PaO2, pulmonary function test, and exercise tolerance. Median overall survival was significantly longer in the ILA-IPF group (78.9 months vs 52.2 months, pLCO were significant prognostic factors. The prognosis adjusted by gender, age, FVC, and DLCO was not significantly different between ILA-IPF and non-ILA-IPF. (hazard ratio 0.79, 95% CI 0.56-1.11, p=0.18). Conclusion: No significant difference was observed in disease progression and prognosis between ILA-IPF and non-ILA-IPF. Early diagnosis of IPF in ILA patients is crucial.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3276
Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis
Background: Attention has been focused on identifying cases with a progressive phenotype in interstitial lung abnormalities (ILA). Some ILA cases may be followed up as they are, some may be diagnosed with interstitial lung disease (ILD) as a result of work-up, including a surgical lung biopsy. Aims: To evaluate if the cases of idiopathic pulmonary fibrosis (IPF) with definition of ILA (ILA-IPF) differed from those of IPF without ILA (non-ILA-IPF). Methods: Of the patients diagnosed with IPF from January 2008 to July 2015, 149 ILA-IPF cases and 120 non-ILA-IPF cases were examined for various variables including disease progression and prognosis. ILA is defined based on the incidental identification of CT abnormality that are potentially compatible with ILD without previous clinical suspicion of ILD (Lancet Respir Med 2020; 8: 726–37). Results: In patients’ background at diagnosis of the two groups, significant differences were observed in age, PaO2, pulmonary function test, and exercise tolerance. Median overall survival was significantly longer in the ILA-IPF group (78.9 months vs 52.2 months, pLCO were significant prognostic factors. The prognosis adjusted by gender, age, FVC, and DLCO was not significantly different between ILA-IPF and non-ILA-IPF. (hazard ratio 0.79, 95% CI 0.56-1.11, p=0.18). Conclusion: No significant difference was observed in disease progression and prognosis between ILA-IPF and non-ILA-IPF. Early diagnosis of IPF in ILA patients is crucial.
- Open Access
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1834
Prognosis in Non-IPF with Progressive Fibrotic Phenotype Results in Similar Prognosis in IPF
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1834
Open AccessPrognosis in Non-IPF with Progressive Fibrotic Phenotype Results in Similar Prognosis in IPF